Loomis, Sayles & Company
BIO icon

Loomis, Sayles & Company’s Bio-Rad Laboratories Class A BIO Stock Holding History

Loomis, Sayles & Company’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-143
Closed -$60K – 871
2022
Q3 		$60K Sell
143
-285
-67% -$142K ﹤0.01% 561
2022
Q2 		$212K Sell
428
-363
-46% -$189K ﹤0.01% 492
2022
Q1 		$446K Buy
791
+363
+85% +$219K ﹤0.01% 499
2021
Q4 		$323K Buy
+428
New +$320K ﹤0.01% 535
2021
Q1 		– Sell
-20
Closed -$12K – 842
2020
Q4 		$12K Buy
+20
New +$11.4K ﹤0.01% 689
2015
Q4 		– Sell
-77
Closed -$10K – 1050
2015
Q3 		$10K Buy
+77
New +$11.1K ﹤0.01% 902

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Loomis, Sayles & Company's BIO Position: Q4 2022 in Review

Loomis, Sayles & Company sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 143 shares — an estimated $60K sold.

Loomis, Sayles & Company first reported a position in BIO in Q3 2015 and held it in 6 quarters. The position peaked at $446K in Q1 2022. 470 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

  • Loomis, Sayles & Company reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 143 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $60K.
  • Loomis, Sayles & Company first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and held it in 6 quarters.
  • Loomis, Sayles & Company's Bio-Rad Laboratories Class A position peaked at $446K in Q1 2022.
  • 470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Loomis, Sayles & Company's 13F filing for Q4 2022, filed 10 Feb 2023.